METHODS AND COMPOSITIONS FOR TREATING BACTERIAL INFECTION

• US 20100331351A1
• Filed: 01/21/2010
• Published: 12/30/2010
• Est. Priority Date: 01/21/2009
• Status: Active Grant

• Current Assignee: Board of Regents of the University of Michigan (University of Michigan), Curators of the University of Missouri (University of Missouri)
• Original Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Inventors: Larsen, Scott, Ginsburg, David, Yestrepsky, Bryan, Sun, Hongmin
• Granted Patent: US 8,501,722 B2
• Time in Patent Office: Days
• US Class Current: 514/267
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: G01B 11/0625 with measurement of absorption or reflection
• CPC Class Codes: G01B 11/0683 measurement during deposition or removal of the layer
• CPC Class Codes: G05B 13/048 using a predictor
• CPC Class Codes: G05B 19/4097 characterised by using design data to control NC machines, e.g. CAD/CAM G05B19/4093 takes precedence
• CPC Class Codes: G05B 2219/35028 Adapt design as function of manufacturing merits, features, for manufacturing, DFM
• CPC Class Codes: G05B 2219/35081 Product design and process machining planning concurrently, machining as function of design
• CPC Class Codes: H01L 31/0322 comprising only AIBIIICVI chalcopyrite compounds, e.g. Cu In Se2, Cu Ga Se2, Cu In Ga Se2
• CPC Class Codes: H01L 31/18 Processes or apparatus specially adapted for the manufacture or treatment of these devices or of parts thereof
• CPC Class Codes: H01L 31/20 such devices or parts thereof comprising amorphous semiconductor materials
• CPC Class Codes: H01L 31/206 Particular processes or apparatus for continuous treatment of the devices, e.g. roll-to roll processes, multi-chamber deposition
• CPC Class Codes: Y02E 10/541 CuInSe2 material PV cells
• CPC Class Codes: Y02P 70/50 Manufacturing or production processes characterised by the final manufactured product
• CPC Class Codes: Y02P 90/02 Total factory control, e.g. smart factories, flexible manufacturing systems [FMS] or integrated manufacturing systems [IMS]

Abstract

The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and research use. In particular, the present invention provides compounds as therapeutic agents against bacterial infections.

Claims

1. A pharmaceutical composition that inhibits the pathogenticity of Group A Streptococcus, comprising a compound that inhibits the expression or activity of streptokinase from said Group A Streptococcus, wherein said compound is selected from the group consisting of

2. The composition of claim 1, wherein said compound is selected from the group consisting of

3. The composition of claim 1, further comprising a pharmaceutically acceptable carrier.

4. The composition of claim 1, wherein said composition inhibits infectivity of said Group A Streptococcus.

5. The composition of claim 1, wherein said composition further comprises a known antibiotic compound.

6. A method of inhibiting the pathogenticity of Group A Streptococcus, comprising contacting said Group A Streptococcus with a compound that inhibits the expression or activity of streptokinase from said Group A Streptococcus.

7. The method of claim 6, wherein said compound is

8. The method of claim 7, wherein said compound is selected from the group consisting of

9. The method of claim 6, wherein said compound is selected from the group consisting of

10. The method of claim 6, wherein said composition inhibits infectivity of said Group A Streptococcus.

11. The method of claim 6, further comprising the step of contacting said Group A Streptococcus with a known antibiotic compound.

12. A high throughput method of screening for compounds that inhibit the pathogenicity of Group A Streptococcus, comprising:

a) contacting a plurality of Group A Streptococcus samples, wherein said Group A Streptococcus comprises a selectable marker gene under the control of a streptokinase promoter, with a plurality of test compounds;

b) measuring the pathogenicity of said samples under selectable conditions; and

c) identifying test compounds that inhibit the pathogenicity of said Group A Streptococcus.